MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q2
hinzugefügt 10.08.2022
Liminal BioSciences Anteile 2011-2026 | LMNL
Anteile Jährlich Liminal BioSciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 30.2 M | 16.1 M | 16.1 M | 828 K | 684 K | 598 K | 571 K | 578 K | 490 K | 420 K | - |
Alle Zahlen in CAD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 30.2 M | 420 K | 6.65 M |
Anteile Vierteljährlich Liminal BioSciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 29.9 M | - | - | - | 23.4 M | - | - | - | 16.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in CAD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 29.9 M | 16.5 M | 23.3 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
187 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
266 M | $ 1.36 | -2.52 % | $ 362 M |  Britain |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | USA |
 |
DBV Technologies S.A.
DBVT
|
140 M | $ 20.25 | -0.54 % | $ 2.83 B | France |
 |
Dyadic International
DYAI
|
36.2 M | $ 0.87 | 0.59 % | $ 31.5 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
2.41 B | $ 3.78 | 4.83 % | $ 9.09 B |  Australia |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
6.28 M | $ 2.6 | -2.26 % | $ 16.3 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Fate Therapeutics
FATE
|
119 M | $ 1.14 | -4.2 % | $ 135 M | USA |
 |
Forte Biosciences
FBRX
|
12.9 M | $ 26.44 | - | $ 342 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
Fennec Pharmaceuticals
FENC
|
28.6 M | $ 6.16 | -4.05 % | $ 176 M | USA |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
Amicus Therapeutics
FOLD
|
308 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |
 |
Fulcrum Therapeutics
FULC
|
63.4 K | $ 7.57 | -3.32 % | $ 480 K | USA |
 |
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Galectin Therapeutics
GALT
|
63.9 M | $ 2.28 | -11.13 % | $ 146 M | USA |
 |
Gilead Sciences
GILD
|
1.24 B | $ 138.34 | -1.28 % | $ 172 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
931 K | $ 0.54 | 4.28 % | $ 503 K |  Israel |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Genmab A/S
GMAB
|
630 M | $ 27.14 | -2.2 % | $ 17 B |  Danmark |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
244 M | $ 88.2 | -3.37 % | $ 27.2 B | Germany |
 |
Gossamer Bio
GOSS
|
229 M | $ 0.32 | -7.11 % | $ 73.1 M | USA |
 |
Coherus BioSciences
CHRS
|
117 M | $ 1.62 | -3.29 % | $ 190 M | USA |
 |
Grifols, S.A.
GRFS
|
682 M | $ 7.98 | -3.04 % | $ 6.83 B |  Spain |
 |
Akari Therapeutics, Plc
AKTX
|
67.3 B | $ 3.5 | -1.13 % | $ 236 B | Britain |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
GT Biopharma
GTBP
|
5.51 M | $ 0.41 | -8.56 % | $ 2.26 M | USA |
 |
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
131 M | $ 316.69 | -4.13 % | $ 41.5 B | USA |
 |
Halozyme Therapeutics
HALO
|
120 M | $ 63.72 | 1.01 % | $ 7.64 B | USA |
 |
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
25.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
15.3 M | - | 4.14 % | $ 49.1 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
57.5 M | $ 27.53 | -0.67 % | $ 1.58 B | USA |
 |
Burford Capital Limited
BUR
|
219 M | $ 4.53 | 1.0 % | $ 726 M | Britain |
 |
Atreca
BCEL
|
38.6 M | - | -11.76 % | $ 5.79 M | USA |